19:25 , Dec 21, 2018 |  BC Week In Review  |  Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
14:04 , Dec 19, 2018 |  BC Extra  |  Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma...
00:57 , Sep 15, 2015 |  BC Extra  |  Financial News

Acacia plans L150M IPO

Acacia Pharma Ltd. (Cambridge, U.K.) plans to raise L150 million ($232 million) in an IPO on the London Stock Exchange in October, according to a person familiar with the company. JPMorgan Cazenove and Canaccord are...
01:51 , Jun 10, 2015 |  BC Extra  |  Financial News

Circassia raises L275M to fund pair of acquisitions

Allergy company Circassia Pharmaceuticals plc (LSE:CIR) raised L275 million ($420.1 million) through the sale of 95.5 million shares at L2.88 in a placing and open offer underwritten by JPMorgan Cazenove and Peel Hunt. The sale...
01:13 , May 16, 2015 |  BC Extra  |  Company News

Circassia bids for respiratory plays Aerocrine, Prosonix

Circassia Pharmaceuticals plc (LSE:CIR) said it intends to acquire a pair of respiratory companies and raise about L275 million ($424.2 million) via a placing and open share offering. Circassia proposed to buy asthma diagnostics company...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

APD421: Phase III data

Pooled data from a total of 626 evaluable surgical patients at moderate to high risk of PONV in a pair of double-blind Phase III trials showed that a single dose of IV APD421 met the...
01:42 , Oct 8, 2014 |  BC Extra  |  Clinical News

Acacia seeks options after hitting in PONV Phase III

Acacia Pharma Ltd. (Cambridge, U.K.) said its lead product APD421 reduced the incidence of post-operative nausea and vomiting in two Phase III trials of adult surgical patients at moderate to high risk for PONV. Acacia,...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Company News

ProStrakan, Kyowa Hakko Kirin deal

Kyowa Hakko Kirin will acquire ProStrakan for 130p per share, or about £292 million ($474 million) in cash. The price is a 20% premium to ProStrakan's close of 108.90p on Feb. 18, before the deal...
01:49 , Feb 23, 2011 |  BC Extra  |  Company News

Kyowa to buy ProStrakan to gain beachhead in EU, U.S.

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will acquire ProStrakan Group plc (LSE:PSK) for 130p per share, or about L292 million ($474 million) in cash. The price is a 20% premium to ProStrakan's close of 108.90p...
07:00 , Jul 24, 2006 |  BioCentury  |  Finance

Ebb & Flow

The $365 million in cash that Gilead (GILD) is paying for the 87% of Corus it did not already own is giving the private company a total imputed value of $420 million, almost certainly a...